Roche has withdrawn a cancer drug from Greece, saying that a series of government-imposed price discounts have made it impossible to market the drug there.
IQVIA’s Murray Aitken examines the potential for savings from a new wave of oncology biosimilars – but says payers have to invest in education and incentives to maximise uptake.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
